The peptide
family tree
A map of major research-peptide families and their lineages. Compounds we carry are marked and link to their page; the rest are shown for research context only.
Classifications below describe peptide lineage and mechanism for research context only. They are not therapeutic claims, medical advice, or claims about catalystX products, which are supplied for research use only.
The incretin-agonist lineage. Members extend half-life, add receptor targets, or alter the metabolic signal.
Endogenous source molecule associated with the GLP-1 lineage.
- Status
- source molecule
Weekly GLP-1 agonist.
- Status
- approved drug
- Tier
- A
Daily GLP-1 agonist.
- Status
- approved drug
- Tier
- A
First GLP-1 agonist.
- Status
- approved drug
- Tier
- B
Short-acting GLP-1 agonist.
- Status
- approved drug
- Tier
- C
Analogs of growth hormone–releasing hormone designed to raise endogenous GH pulses.
Endogenous 44-amino-acid hypothalamic hormone.
- Status
- endogenous
First 29 amino acids of GHRH.
- Tier
- A
Modified GRF(1-29).
- Tier
- B
CJC-1295 variant with DAC to extend half-life.
- Tier
- B
GH-secretagogue lineage working through the ghrelin receptor rather than the GHRH receptor.
Endogenous GH-release hormone.
- Status
- endogenous
- Tier
- A
Potent ghrelin-receptor secretagogue.
- Tier
- B
Oral non-peptide mimetic associated with the ghrelin-receptor branch.
- Tier
- B
Potent GH-releasing peptide.
- Tier
- C
First-generation GH-releasing peptide.
- Tier
- C
Selective ghrelin-receptor GH secretagogue.
- Tier
- C
Analogs of α-MSH, the endogenous melanocortin involved in pigmentation and appetite signaling.
Endogenous melanocortin hormone.
- Status
- endogenous
- Tier
- A
Melanocortin analog.
- Status
- approved drug
- Tier
- A
Melanocortin analog.
- Status
- approved drug
- Tier
- B
Research-only melanocortin analog.
- Status
- research-only
- Tier
- D
Peptides isolated from thymic tissue; the α-family is associated with immune research and the β-family with actin-based tissue-repair research.
Thymosin alpha-family peptide.
- Status
- approved in some countries
- Tier
- B
Thymosin beta-family peptide associated with tissue-repair research.
- Status
- research
- Tier
- C
- Purity
- ≥ 98.9%
- Batch
- TB500-2604
Fragments of body-protection compound, a stable gastric pentadecapeptide first isolated in 1993.
Arginate salt form developed for improved stability.
- Tier
- D
Topical short peptides that migrated from wound-healing research into cosmeceuticals.
Topical cosmetic peptide.
- Status
- cosmetic
- Tier
- B
Copper-bound peptide associated with skin and hair research.
- Status
- cosmetic/research
- Tier
- B
- Purity
- ≥ 99.6%
- Batch
- GHKCU-2605
Cosmetic peptide associated with collagen-signaling research.
- Status
- cosmetic
- Tier
- C
Copper-tripeptide variant.
- Status
- cosmetic/research
- Tier
- D
Short organ-targeted peptides developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology.
Khavinson bioregulator associated with thymus research.
- Tier
- C
Khavinson bioregulator associated with bronchial tissue.
- Tier
- D
Khavinson bioregulator associated with cardiac tissue.
- Tier
- D
Khavinson bioregulator associated with cartilage.
- Tier
- D
Khavinson bioregulator associated with respiratory mucosa.
- Tier
- D
Khavinson bioregulator associated with cortex.
- Tier
- D
Khavinson bioregulator associated with pineal / longevity research.
- Tier
- D
Khavinson bioregulator associated with liver.
- Tier
- D
Stabilized Epitalon variant.
- Tier
- D
Khavinson bioregulator associated with pancreas.
- Tier
- D
Khavinson bioregulator associated with pineal / neuropeptide research.
- Tier
- D
Khavinson bioregulator associated with prostate.
- Tier
- D
Khavinson bioregulator associated with testicular tissue.
- Tier
- D
Thymus-associated variant.
- Tier
- D
Khavinson bioregulator associated with vascular tissue.
- Tier
- D
Khavinson bioregulator associated with immune research.
- Tier
- D
Khavinson bioregulator associated with hepatic / ovarian tissue.
- Tier
- F
Short Russian-origin neuropeptides designed for intranasal delivery.
Stabilized Selank variant.
- Tier
- C
Tuftsin-derived neuropeptide.
- Tier
- C
ACTH(4-10) analog.
- Tier
- C
Further-stabilized Semax variant.
- Tier
- F
Decapeptide analogs of gonadotropin-releasing hormone.
Endogenous decapeptide.
- Status
- endogenous
- Tier
- B
GnRH analog.
- Status
- approved drug
- Tier
- A
Long-acting GnRH agonist.
- Status
- approved drug
- Tier
- B
GnRH agonist.
- Status
- approved drug
- Tier
- B
Intranasal GnRH agonist.
- Status
- approved drug
- Tier
- B
GnRH agonist.
- Status
- approved drug
- Tier
- B
GnRH agonist.
- Tier
- C
Notable peptides that do not share a clean lineage with the families above.
Standalone hormone peptide.
- Status
- approved drug
- Tier
- A
Vasopressin analog.
- Status
- approved drug
- Tier
- B
Cardiolipin stabilizer.
- Status
- investigational
- Tier
- B
Long-acting IGF-1 analog.
- Tier
- C
Delta sleep-inducing peptide.
- Tier
- D
Truncated IGF-1 form.
- Tier
- D
Cathelicidin antimicrobial peptide.
- Tier
- D
Tiers rank how extensively a compound has been characterized in the literature, S (most) → F (sparse) — not quality or suitability.
Reading the tiers
Each compound carries a tier (S–F) — a neutral research-maturity ranking carried from the source dataset, reflecting how extensively a compound has been characterized in the literature. It is not a claim about quality, safety, or suitability for any use, and says nothing about the compounds catalystX supplies, which are sold for research use only.
- S
- Most characterized
- A
- Extensively studied
- B
- Well studied
- C
- Moderately studied
- D
- Emerging
- F
- Sparse data